“During the period from October 25, 2013 to Marc
Post# of 72440
(Total Views: 141)
Posted On: 11/22/2017 2:09:47 PM
“During the period from October 25, 2013 to March 5, 2015, the Company had completed sales to Aspire Capital totaling 8,890,379 shares of common stock generating gross proceeds of approximately $20 million."
"During the period from March 30, 2015 to June 30, 2017, the Company had completed sales to Aspire Capital totaling 14.7 million shares of common stock generating gross proceeds of approximately $16 million."
"From July 1, 2017 to September 1, 2017, the Company generated additional proceeds of approximately $2.1 million under the March 2015 common stock purchase agreement with Aspire Capital from the sale of approximately 2.6 million shares of its common stock."
8,890,379 + 14,700,000 + 2,600,000 = 26,190,379 shares
5% of the current OS is ~7 million shares. We know Aspire has to file a Schedule 13G if it owns 5% or more. The fact that Aspire hasn't filed it means they've sold at least 19.2 millions shares (and counting), or ~73% of the shares sold to them by IPIX.
"During the period from March 30, 2015 to June 30, 2017, the Company had completed sales to Aspire Capital totaling 14.7 million shares of common stock generating gross proceeds of approximately $16 million."
"From July 1, 2017 to September 1, 2017, the Company generated additional proceeds of approximately $2.1 million under the March 2015 common stock purchase agreement with Aspire Capital from the sale of approximately 2.6 million shares of its common stock."
8,890,379 + 14,700,000 + 2,600,000 = 26,190,379 shares
5% of the current OS is ~7 million shares. We know Aspire has to file a Schedule 13G if it owns 5% or more. The fact that Aspire hasn't filed it means they've sold at least 19.2 millions shares (and counting), or ~73% of the shares sold to them by IPIX.
(1)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼